Audit on low molecular weight heparin prescription;Audit sur la prescription des heparines de bas poids moleculaire

Journal de Pharmacie Clinique

Volumn 15, Issue 3, 1996, Pages 231-234

  Callaert, S ^a   Chouaid, C ^a   Causse, R ^a   Thebault A ^a  

^a CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

Author keywords

audit; low molecular weight heparin; prevention

Indexed keywords

DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ARTICLE; HUMAN; MAJOR CLINICAL STUDY; PRESCRIPTION; VEIN THROMBOSIS;

EID: 0029852802     PISSN: 02911981     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Allaart CF, Poort SR, Rosendaal FR, et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-8.
2. Andaz S, Shields DA Scurr JH, et al. Role of low molecular weight heparins in the prevention and treatment of venous thromboembolism after surgery. Phlebology 1992; 9: 2-7.
3. Anderson DR, O'Brien BJ, Levine MN, et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Ann Intern Med 1993; 119: 1105-12.
4. Anderson FA, Wheeler HB, Goldberg RJ, et al. The prevalence of risk factors for venous thromboembolism among hospital patients. Arch Intern Med 1992; 152: 1660-4.
5. Anonyme Conférence de consensus, prophylaxie des thromboses veineuses profondes et des embolies pulmonaires postopératoires (chirurgie générale, gynécologique et orthopédique), 8 mars 1991, Paris. Ann Fr Anesth Rean 1991, 10. 417-21.
6. Anonyme. Prophylaxie des thromboses veineuses postopératoires: recommandations de l'Assistance publique-Hôpitaux de Paris. Fiche technique Sang Thrombose Vaisseaux 1995; 7: 119-20.
7. Belch JJ, Lowe GD, Ward AG, et al. Prevention of deep vein thrombosis in medical patients by low-dose heparin. Scot Med J 1981, 26: 115-7.
8. Berggvist D Review of clinical trials of low molecular weitht heparins. Eur J Surg 1992; 158: 67-78.
9. Brenkel IJ, Clancy MJ. Total hip replacement and antithrombotic prophylaxis Br J Hosp Med 1989, 42: 282-4.
10. Busby W, Bayer A, Pathy J. Pulmonary embolism in the elderly. Age Ageing 1988; 17: 20-69.
11. Byrd RB, Divertie MB, Spittel JA. Bronchogenic carcinoma and thrombembolic disease. J Amer Med Ass 1967; 202: 1019-22.
12. Cade JF. High risk of the critically ill for venous thromboembolism. Crit Care Med 1982; 10: 448-50.
13. Caprini JA, Arcelus JI, Hoffman K, et al. Prévention of venous thromboembolism in North America: Results of a surgery among general surgeons. J Vasc Surg 1994; 20. 751-8
14. Clarke-Pearson DL, Delong ER, Synan IS, et al. A controlled trial of two low dose heparin regimens for the prevention of deep vein thrombosis. Obstet Gynecol 1990; 75: 684-9.
15. Dahan R, Houlbert D, Caulin E Prevention of deep veinous thrombosis in elderly medical patients by a low molecular weight heparin: a randomized double blind trial. Haemostasis 1986; 16: 159-64.
16. Forette B, Wolmark Y. Nadroparine calcique dans la prévention de la maladie thrombo-embolique chez le sujet âgé. Étude de la tolérance. Press Med 1995; 24. 567-71.
17. Frisbie JH, Sasahara AA. Low dose heparin in prophylaxis for deep venous thrombosis in acute spinal cord injury patients: a controlled study. Paraplegia 1981; 19: 343-6.
18. Gallus AS. Anticoagulants in the prevention of venous thromboembolism. Baillieres Clin Haematol 1990; 3: 651-84.
19. Green D, Hirsh H, Heit J, et al. Low molecular weight heparin: a critical analysis of clinical trials. N Engl J Med 1994; 46: 89-109.
20. Halkin H, Goldberg J, Modan M, et al. Reduction of mortality in general medical in patients by low dose heparin prophylaxis. Ann Intern Med 1982; 96: 561-5.
21. Hirsh J. Prevention of venous thrombosis in patients undergoing major orthopaedic surgical procedures. Acta Chir Scand 1990; S556: 30-5.
22. Hull RD, Raskob GE, Pineo GF, et al. Subcutaneous low-molecular weight heparin compared with continous intravenous heparin in the treatment of proximo-vein thrombosis. N Engl J Med 1992, 326: 975-83
23. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1992; 102: 408S-25S.
24. Imperials TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. J Amer Med Ass 1994, 271. 1780-5.
25. Jonsson I, Hallgrimson J. Comparative disease patterns in the elderly and the very old. A retrospective autopsy study. Age Ageing 1983, 12: 111-5.
26. Jorgensen LN, Wilie-Jorgensen P, Hauch O. Prophylaxis of postoperative thromboembolism with low molecular weight heparins. Br J Surg 1993; 80: 689-704.
27. Kakkar VV. Efficacy and safety of clivarin and other LMWHs in general surgery: a meta analysis. Blood Coag Fibrinol 1993; 4: S23-S7.
28. Lairy G, Saltiel JC, Berrissoul F, et al. Audit de to prescription des héparines de bas poids moléculaire. La Pharmacie Hospitalière Française 1993, 105: 181-90
29. Leizorovicz A, Haugh MC, Chapuis FR, et al. Low molecular weight heparin in prevention of perioperative thrombosis. Br Med J 1992; 305: 913-20.
30. McCarthy SR, Robertson D, Turner U, et al. Low dose heparin as a prophylaxis against deep-vein thrombosis after acute stroke. Lancet 1977; 2. 800-1.
31. McCarthy ST, Turner J. Low dose subcutaneous heparin in the prevention of deep-vein thrombosis and pulmonary embolie following acute stroke. Age Ageing 1986, 15: 84-8.
32. National Institute of Health. Consensus development conference statement prevention of venous thrombosis and pulmonary embolism. J Amer Med Ass 1986; 256: 744-9.
33. Owen CA, Bowie EJW. Predisposing factors in thrombosis. In: H.C. IK, Bowie JW, eds. Thrombosis. Philadelphia: Saunders, 1982.
34. Samama M, Boissel JP, Combe Tamzali S, et al. Clinical studies with low molecular weight heparin in the prevention and treatment of venous thromboembolism. Ann NY Acad Sci 1988: 556-86.
35. Simmouns AV, Sheppard MA, Cox AE. Deep venous thrombosis after myocardial infarction: predisposing factors. Br Heart J 1973, 35: 623-5.
36. Thomas DP. Curent status of low molecular weight heparin. Thromb Haemost 1986; 56: 241-2.
37. Thromboembolic Risk Factor (THRIFT). Risk of and prophylaxis for venous thromboembolism in hospital patients. Consensus Group. Br Med J 1992, 305: 567-74.
38. Warlow C, Ferry G, Kenmure CE. A double blind trial of low doses of subcutaneous heparin in the prevention of deep vein thrombosis after myocardial infarction. Lancet 1973; 2: 934-6.
39. Watson N. Anticoagulant therapy in the prevention of venous thrombosis and pulmonary embolism in the spinal cord injury. Paraplegia 1978; 16: 265-9.
40. Wille-Jorgensen P, Hausch O, Dimo B, Christensen SW, Jensen R, Hasen B Prophylaxis of deep venous thrombosis after abdominal operation. Surg Gynecol Obstet 1991; 1131-5.